Physician profile
John M Ham
NPI 1104834639
$292.31
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2021: $175 · 2022: $14.63.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $93.84 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.62 | 2021-2022 | |
| Veloxis Pharmaceuticals, INC. | $40.64 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $39.58 | 2019-2021 | |
| Vyera Pharmaceuticals, LLC | $19.65 | 2019 | |
| Genentech, INC. | $18.46 | 2019 | |
| Novo Nordisk INC | $16.19 | 2021 | |
| Medtronic, INC. | $12.33 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.